RxDoctor Payments Data

Jade Breeback, PA

Physician Assistant · Kernersville, NCNPI 1922351188

Payments from drug & device makers

$7,611in general payments, 2019–2025

Across 474 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$890
  • Novo Nordisk$883
  • Pfizer$727
  • Abbott$611
  • Lilly USA, LLC$459
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,611 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$26,856
Medicare patients
78
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$64,594
MounjaroTirzepatide42$61,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$45,482
FarxigaDapagliflozin Propanediol48$45,175
TrulicityDulaglutide28$40,070
LinzessLinaclotide26$24,679
MyrbetriqMirabegron18$18,589
BelsomraSuvorexant23$17,604
Repatha SyringeEvolocumab15$16,906
EliquisApixaban25$15,896
Tresiba Flextouch U-200Insulin Degludec14$14,845
Humalog Kwikpen U-200Insulin Lispro17$13,607
XareltoRivaroxaban12$12,472
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$12,349
JardianceEmpagliflozin14$11,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$459$101,81470 claims
Novo NordiskOzempic$883$64,59446 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$890$63,11786 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$72$55,45473 claims
AbbVieLinzess, Synthroid$1,228$26,39263 claims
Astellas Pharma US IncMyrbetriq$175$18,58918 claims
MerckBelsomra$11$17,60423 claims
PfizerEliquis$727$15,89625 claims
Johnson & JohnsonXarelto$93$12,47212 claims
Boehringer IngelheimJardiance$115$11,86414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Kernersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →